INOVIO Pharmaceuticals (INO) Stock Price: Why It Rose Over 14% Today

By Amit Chowdhry ● May 27, 2022
  • The stock price of INOVIO Pharmaceuticals Inc (NASDAQ: INO) increased by over 14% during intraday trading today. This is why.

The stock price of INOVIO Pharmaceuticals Inc (NASDAQ: INO) increased by over 14% during intraday trading today. Investors are responding positively to INOVIO announcing the results from the company’s novel Phase 1/2 trial of INO-5401 and INO-9012 in combination with PD-1 inhibitor Libtayo (cemiplimab) in the treatment of newly diagnosed glioblastoma (GBM), including encouraging median overall survival (OS) data from 52 subjects. 

The median OS duration in unmethylated MGMT (Cohort A) was 17.9 months. Median OS data in MGMT Methylated patients (Cohort B) are being presented for the first time, at a median of 32.5 months, which compares favorably to historical comparisons (23.2-25 months).

Overall, INO-5401 + INO-9012 was demonstrated to be tolerable and immunogenic when administered with Libtayo and RT/TMZ (radiation and temozolomide) to newly diagnosed GBM patients. And INO-5401 elicited antigen-specific T cells that may infiltrate GBM tumors. And the data from this study was selected to be presented in an oral presentation by Dr. David Reardon on Monday, June 6, 2022, at the 2022 American Society of Clinical Oncology (ASCO) at the McCormick Place Convention Center in Chicago, Illinois.

Presentation Details: June 6, 2022, 12:42 – 12:54 p.m. CDT 

Presenting Author: David A. ReardonCentral Nervous System Tumors Session

Abstract #2004: Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.